Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719260 | 0.82 | HTT (0.40) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL8633097 | 0.79 | AOC3 (0.39) | FFAR1ACHETDP1 | |
| SCHEMBL2149793 | 0.74 | ACHE (0.41) | MEN1KMT2AACHEALDH1A1MAPT | |
| SCHEMBL2150506 | 0.74 | ACHE (0.41) | MEN1KMT2AACHEALDH1A1MAPT | |
| SCHEMBL12319059 | 0.73 | KDM4E (0.41) | CHRNA7FFAR1MEN1KMT2AACHE | |
| SCHEMBL1726813 | 0.71 | CHRNA7 (0.38) | MLKLCHRNA7MEN1KMT2AACHE | |
| SCHEMBL9771549 | 0.69 | NQO1 (0.54) | FFAR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL13053842 | 0.68 | AGXT (0.48) | FFAR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL20710810 | 0.68 | LTA4H (0.41) | FFAR1MEN1KMT2AACHEMAPT | |
| SCHEMBL10683339 | 0.67 | CHRNA7 (0.52) | MLKLCHRNA7MEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460796-A1 | INDOLE DERIVATIVE | Hodogaya Chemical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120052427-A1 | INDOLE DERIVATIVES | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052427-A1 | INDOLE DERIVATIVES | SLC43A1, SLC19A1, SLC7A5 | MLKL 4240/4885CHRNA7 999/4885FFAR1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.